Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study

Annals of Oncology

Volumn 12, Issue 11, 2001, Pages 1619-1630

  Paulussen, M ^a   Ahrens, S ^a   Lehnert, M ^b   Taeger, D ^a   Hense, H W ^a   Wagner, A ^a   Dunst, J ^c   Harms, D ^d   Reiter, A ^e   Henze, G ^f   Niemeyer, C ^g   Gobel U ^h   Kremens, B ⁱ   Folsch U R ^d   Aulitzky, W E ^j   Voute P A ^k   Zoubek, A ^l   Jurgens H ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Epidemiological Cancer Registry of Münster   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f HUMBOLDT UNIVERSITY   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^j ROBERT BOSCH HOSPITAL   (Germany)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l ST ANNA CHILDREN S HOSPITAL   (Austria)

more..

Author keywords

Cytostatic drug therapy; Ewing tumors; Second malignancies

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUSTRIA; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; EWING SARCOMA; FEMALE; GERMANY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NETHERLANDS; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SECOND CANCER; SQUAMOUS CELL CARCINOMA; STANDARDIZATION; STATISTICAL ANALYSIS; TUMOR BIOPSY; WHOLE BODY RADIATION;

EID: 0035690095     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013148730966     Document Type: Article

References (50)

1. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas
2. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children
3. Prognostic factors in patients with localized Ewing's sarcoma: The effect on survival of actual received drug dose intensity and of histologic response to induction therapy
4. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults
5. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma
6. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: A report from the second intergroup study
7. Dose intensity of chemotherapy for childhood cancer
8. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarecoma family of tumors
9. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone
10. Ewing sarcoma of the rib: Results of an intergroup study with analysis of outcome by timing of resection
11. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: A feasibility study at St. Jude Children's Researh Hospital
12. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure
13. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: An interim report
14. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia
15. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
16. Second malignancies after treatment for Ewing's sarcoma: A report of the CESS-studies
17. Second malignancies after Ewing's sarcoma: Radiation dose-dependency of secondary sarcomas
18. Bone sarcomas linked to radiotherapy and chemotherapy in children
19. Risk of radiation-related subsequent malignant tumors in survivors of Ewing's sarcoma
20. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: The Dana-Farber Cancer Institute/Children's Hospital experience
21. Secondary cancers after Ewing sarcoma and Ewing sarcoma as second malignant neoplasm
22. Late effects of therapy in adult survivors of osteosarcoma and Ewing's sarcoma
23. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors
24. [EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study) - Preliminary results] EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study) - Erste Ergebnisse
25. Small-cell pediatric tumors: History, immunohistochemistry, and electron microscopy
26. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents
27. Morphological grades of regression in osteosarcoma after polychemotherapy - Study COSS 80
28. Ewing tumors with primary lung mestastases: Survival analysis of 114 (European Intergroup) Ewing Sarcoma Studies patients
29. Primary metastatic (stage IV) Ewing tumor. Survival analysis of 171 patients from the EICESS studies
30. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma
31. Nonparametric estimation from incomplete observations
32. How to establish equivalence when data are censored: A randomized trial of treatments for B non-Hodgkin lymphoma
33. Improved methodology for analyzing local and distant recurrence
34. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer
35. Morbidität und Mortalität an bösartigen Neubildungen im Saarland 1991
36. Morbidität und Mortalität an bösartigen Neubildungen im Saarland 1992
37. Morbidität und Mortalität an bösartigen Neubildungen im Saarland 1993
38. Morbidität und Mortalität an bösartigen Neubildungen in Saarland 1994 und 1995
39. A stand-alone windows applications for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies
40. Secondary tumors in bone sarcomas after treatment with chemotherapy
41. Multiple primary neoplasms in childhood: Data from the German Children's Cancer Registry
42. Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21;q23)
43. Secondary leukemias induced by topoisomerase-targeted drugs
44. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks
45. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma
46. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia
47. Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: Follow-up of 725 patients from a single centre over a period of 26 years
48. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma
49. Secondary malignancies after bone marrow transplantation in adults